Christopher A. Kerfoot

579 total citations
16 papers, 462 citations indexed

About

Christopher A. Kerfoot is a scholar working on Oncology, Molecular Biology and Physiology. According to data from OpenAlex, Christopher A. Kerfoot has authored 16 papers receiving a total of 462 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Physiology. Recurrent topics in Christopher A. Kerfoot's work include Tuberous Sclerosis Complex Research (5 papers), Histiocytic Disorders and Treatments (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Christopher A. Kerfoot is often cited by papers focused on Tuberous Sclerosis Complex Research (5 papers), Histiocytic Disorders and Treatments (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Christopher A. Kerfoot collaborates with scholars based in United States, Canada and Germany. Christopher A. Kerfoot's co-authors include Harry V. Vinters, Jeffrey E. DeClue, Susan A. Rotenberg, Weidong Huang, Michael W. Johnson, Gary W. Mathern, R. Wienecke, Samuel H. Pepkowitz, Sung‐Hye Park and Vadims Poukens and has published in prestigious journals such as Cancer Research, Acta Neuropathologica and Journal of Histochemistry & Cytochemistry.

In The Last Decade

Christopher A. Kerfoot

15 papers receiving 449 citations

Peers

Countries citing papers authored by Christopher A. Kerfoot

Since Specialization

Citations

This map shows the geographic impact of Christopher A. Kerfoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Kerfoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Kerfoot more than expected).

Fields of papers citing papers by Christopher A. Kerfoot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher A. Kerfoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Kerfoot. The network helps show where Christopher A. Kerfoot may publish in the future.

Co-authorship network of co-authors of Christopher A. Kerfoot

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher A. Kerfoot. A scholar is included among the top collaborators of Christopher A. Kerfoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher A. Kerfoot. Christopher A. Kerfoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Abstract B069: Characterization of inflammatory cell patterns and densities using multiplex immunohistochemistry immuno-oncology assays 2018 ·Molecular Cancer Therapeutics ·(unknown), Christopher A. Kerfoot, (unknown), (unknown), Johannes Zimmermann, (unknown), (unknown), (unknown), (unknown), R Korn, Tobias Wiestler, Daša Medříková, (unknown)	1
2	Abstract 1669: Multiplex immunohistochemical staining of PD-L1, PD-1, CD3, CD4, CD8, CD68, FoxP3, and Ki-67 and image analysis of tumor and invasive margin in human FFPE NSCLC tissue 2017 ·Cancer Research ·(unknown), (unknown), J. P. Zheng, (unknown), (unknown), Christopher A. Kerfoot	1
3	Abstract 3396: Optimization of an assay for the detection of PD-L1 by immunohistochemistry in formalin-fixed, paraffin-embedded human tissue and cell lines 2015 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), J. P. Zheng, Ryan S. Lim, (unknown), Christopher A. Kerfoot	1
4	Abstract 899: Combination of PI3K and MEK inhibitor chemosensitivity in human tumor explants and cell lines using the Mosaic Blue assay and relationship to biomarkers by immunohistochemistry 2014 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Ryan S. Lim, Jianping Zheng, (unknown), Christopher A. Kerfoot	1
5	Expression of XPG protein in human normal and tumor tissues. 2013 ·PubMed ·Miguel Aracil, (unknown), Marta Martínez, (unknown), Victoria Moneo, Juan Fernando Martínez-Leal, (unknown), Christopher A. Kerfoot, Carlos M. Galmarini	5
6	Level of phosphohistone H3 among various types of human cancers 2012 ·BMJ Open ·Amy Sun, Wei Zhou, Jared Lunceford, Peter R. Strack, (unknown), Christopher A. Kerfoot	24
7	An Anti-Urokinase Plasminogen Activator Receptor Antibody (ATN-658) Blocks Prostate Cancer Invasion, Migration, Growth, and Experimental Skeletal Metastasis In Vitro and In Vivo 2010 ·Neoplasia ·Shafaat A. Rabbani, Bushra Ateeq, Ani Arakelian, Maria Luisa Valentino, David E. Shaw, (unknown), Christopher A. Kerfoot, Andrew P. Mazar	70
8	In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells 2004 ·Cancer Research ·Lorenzo M. Leoni, Brandi Bailey, Christina C. Niemeyer, Jack Reifert, Heather Bendall, (unknown), Christopher A. Kerfoot	22
9	488 VX-944: an inosine monophosphate dehydrogenase inhibitor with unique anti-cancer activity 2004 ·European Journal of Cancer Supplements ·Jugnu Jain, (unknown), Randall Hoover, (unknown), Pamella J. Ford, William Markland, (unknown), Christopher A. Kerfoot, Rebecca Mosher	3
10	Immunohistochemical Analysis of Advanced Human Breast Carcinomas Reveals Downregulation of Protein Kinase Cα 2004 ·Journal of Histochemistry & Cytochemistry ·Christopher A. Kerfoot, Weidong Huang, Susan A. Rotenberg	51
11	Hamartin and Tuberin Expression in Human Tissues 2001 ·Modern Pathology ·Michael W. Johnson, Christopher A. Kerfoot, (unknown), (unknown), Harry V. Vinters	48
12	Cortical Dysplasia, Genetic Abnormalities and Neurocutaneous Syndromes 1999 ·Developmental Neuroscience ·Harry V. Vinters, Sung‐Hye Park, Michael W. Johnson, Paul S. Mischel, (unknown), Christopher A. Kerfoot	33
13	Cerebral Cortical Dysplasia: Giant Neurons Show Potential for Increased Excitation and Axonal Plasticity 1999 ·Developmental Neuroscience ·Christopher A. Kerfoot, Harry V. Vinters, Gary W. Mathern	43
14	Tuberous sclerosis-related gene expression in normal and dysplastic brain 1998 ·Epilepsy Research ·Harry V. Vinters, Christopher A. Kerfoot, (unknown), (unknown), Steven N. Roper, Jeffrey E. DeClue	29
15	Tuberous sclerosis in a 20-week gestation fetus: immunohistochemical study 1997 ·Acta Neuropathologica ·Sung‐Hye Park, Samuel H. Pepkowitz, Christopher A. Kerfoot, Michael J. De Rosa, Vadims Poukens, R. Wienecke, Jeffrey E. DeClue, Harry V. Vinters	79
16	Localization of Tuberous Sclerosis 2 mRNA and its Protein Product Tuberin in Normal Human Brain and in Cerebral Lesions of Patients with Tuberous Sclerosis 1996 ·Brain Pathology ·Christopher A. Kerfoot, Ralf Wienecke, Michael Menchine, (unknown), John C. Maize, Cynthia T. Welsh, Margaret G. Norman, Jeffrey E. DeClue, Harry V. Vinters	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact